Weifa


Weifa is a Norwegian pharmaceutical company headquartered in Oslo with production facilities in Kragerø.
Weifa is one of the world’s largest producers of Metformin hydrochloride and a leading producer of alkaloid opiates. Production facilities follow GMP standards.

History

Weifa was founded by pharmacist Olaf Weider in 1940.

Therapeutic areas

Weifa focuses on three therapeutic areas:
  1. Pain management
  2. Diabetes management
  3. Food supplements

    Products

With a total of over 99 employees, Weifa is today generating an annual turnover of approximately €40 million. Weifa bases its development on 3 criteria:
  1. International expansion
  2. Expertise in pharmaceuticals and fine chemicals
  3. Partnership agreements

    Norway

Weifa has market leadership in pain management products for the Norwegian market, with a portfolio of branded products that includes established brand names such as the Ibux tablets, Paracet tablets and Paralgin Forte tablets. Branded products accounts for approximately 70% of net sales.

Export

Weifa’s leading export markets are Germany and United Kingdom. Besides these two essential export markets, Weifa has a long-standing presence in all the main countries of the European Union, in Eastern Europe, in Africa, in North America, in South America and in Asia.